

ERBB2

Research Grade Trastuzumab deruxtecan (ADC)

Catalog No.	DHC09698A DHC09698B	Quantity:	100 µg 1.0 mg
Alternate Names:	HER2, ENHERTU, DS-8201		
Description:	Research Grade Trastuzumab deruxtecan is an antibody-drug conjugate (ADC) consisting of HER2-directed Trastuzumab and deruxtecan (Dxd), a topoisomerase I inhibitor, used for the study of HER2-positive breast cancer and gastric cancer.		
UniProt ID (target):	P04626		
Specificity:	Human Receptor tyrosine-protein kinase erbB-2 (HER2)		
Concentration:	1.0 mg/ml, lot specific		
Source:	XtenCHO		
Isotype:	Human IgG1 kappa		
Formulation:	0.01M PBS buffer, pH 7.4		
Purity:	> 90% by SEC- HPLC		
Endotoxin Level:	≤ 0.01 EU/µg by LAL analysis		
Purification:	Ion exchange chromatography		
Applications:	Functional studies		
INN:	Trastuzumab deruxtecan		
Storage & Stability:	Store at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year. Avoid freeze/thaw cycles.		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

